Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.
1 report, 1 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
European Commission
executive branch of the European Union